To interrupt the interactions between the adhesin TIGIT (found on NK and T cells) and its primary ligand CD155 (PVR; a dysregulated adhesin found on many tumor cells), Shen, Fu, and Wei et al. tested human and mouse versions of a dimeric fusion of the extracellular domain of TIGIT to Ig-Fc (TIGIT-Fc). TIGIT-Fc demonstrated potent ADCC activity against multiple tumor lines and inhibition of Treg suppression in vitro. Alone and in combination with anti-PD-L1, TIGIT-Fc induced antitumor activity in xenograft models (with allogeneic human T cells) and in syngeneic tumor models. Activity was dependent on NK and CD4+ T cells, and generated immunological memory.
Contributed by Ed Fritsch
ABSTRACT: T-cell immunoreceptor with Ig and ITIM domains (TIGIT) is a checkpoint receptor that mediates both T cell and natural killer (NK) cell exhaustion in tumors. An Fc-TIGIT fusion protein was shown to induce an immune-tolerance effect in a previous report, but the relevance of the TIGIT-Fc protein to tumor immunity is unknown. Here, we found that TIGIT-Fc promotes, rather than suppresses, tumor immunity. TIGIT-Fc treatment promoted the effector function of CD8+ T and NK cells in several tumor-bearing mouse models. TIGIT-Fc treatment resulted in potent T cell- and NK cell-mediated tumor reactivity, sustained memory-induced immunity in tumor re-challenge models, enhanced therapeutic effects via an antibody against PD-L1, and induction of Th1 development in CD4+ T cells. TIGIT-Fc showed a potent antibody-dependent cell-mediated cytotoxicity (ADCC) effect but had no intrinsic effect on tumor cell development. Our findings elucidate the role of TIGIT-Fc in tumor immune reprogramming, suggesting that TIGIT-Fc treatment alone or in combination with other checkpoint receptor blockers is a promising anticancer therapeutic strategy.